Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens.
Best Pract Res Clin Haematol
; 20(2): 171-87, 2007 Jun.
Article
em En
| MEDLINE
| ID: mdl-17448955
ABSTRACT
Minor histocompatibility (H) antigens are key molecules in graft-versus-host disease (GvHD) and the graft-versus-tumour effect after allogeneic stem-cell transplantation (SCT). Today, molecular typing methods allow an easy assessment of differences in minor H antigens between patient and donors, so that the GvHD risk in individual patients can be estimated. However, the large number of minor H antigens prevents matching for them to avoid GvHD. Interestingly, mismatching for minor H antigens might improve the outcome of allogeneic SCT. Some minor H antigens are expressed mainly by malignant cells and can therefore serve as excellent targets for cancer immunotherapy. Thus, mismatching for tumour-expressed minor H antigens allows boosting of the curative effect of allogeneic SCT. Current research is elucidating the impact of e.g. donor immunization, immunodominance, or functional expression of minor H antigens on the extent of the GvH response.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Antígenos de Histocompatibilidade Menor
/
Transplante de Células-Tronco Hematopoéticas
/
Efeito Enxerto vs Tumor
/
Neoplasias
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Pregnancy
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article